Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Saro Armenian"'
Autor:
Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, Melissa M Hudson, Matthew J Ehrhardt, Frederike K Engels, Elizabeth A M Feijen, Heynric B Grotenhuis, Jan M Leerink, Livia Kapusta, Gertjan J L Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J E Tissing, Florent de Vathaire, Paul C Nathan, Leontien C M Kremer, Annelies M C Mavinkurve-Groothuis, Saro Armenian
Publikováno v:
de Baat, E C, van Dalen, E C, Mulder, R L, Hudson, M M, Ehrhardt, M J, Engels, F K, Feijen, E A M, Grotenhuis, H B, Leerink, J M, Kapusta, L, Kaspers, G J L, Merkx, R, Mertens, L, Skinner, R, Tissing, W J E, de Vathaire, F, Nathan, P C, Kremer, L C M, Mavinkurve-Groothuis, A M C & Armenian, S 2022, ' Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines : recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group ', The Lancet Child and Adolescent Health, vol. 6, no. 12, pp. 885-894 . https://doi.org/10.1016/S2352-4642(22)00239-5
The Lancet Child & Adolescent Health, 6, 885-894
The Lancet Child & Adolescent Health, 6, 12, pp. 885-894
The Lancet Child & Adolescent Health, 6, 885-894
The Lancet Child & Adolescent Health, 6, 12, pp. 885-894
Item does not contain fulltext Survivors of childhood cancer are at risk of anthracycline-induced cardiotoxicity, which might be prevented by dexrazoxane. However, concerns exist about the safety of dexrazoxane, and little guidance is available on it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e933dd197d23cbe7070b694086dff1e7
https://doi.org/10.1016/S2352-4642(22)00239-5
https://doi.org/10.1016/S2352-4642(22)00239-5